The Journal of dermatological treatment最新文献

{"title":"Reshaping treatment paradigm in actinic keratosis by using a modified Delphi questionnaire.","authors":"Thomas Dirschka, Marco Ardigò, Maria Concetta Fargnoli, Carla Ferrándiz-Pulido, Yolanda Gilaberte, Ina Hadshiew, Ketty Peris, Rolf-Markus Szeimies","doi":"10.1080/09546634.2025.2487657","DOIUrl":"https://doi.org/10.1080/09546634.2025.2487657","url":null,"abstract":"<p><strong>Purpose: </strong>Actinic keratosis (AK) is the main precursor of invasive cutaneous squamous cell carcinoma (cSCC). Since it is impossible to predict which lesions will progress to cSCC, early treatment of AK is crucial. Although AK treatments are effective, some are associated with local skin reactions that may impact treatment compliance and effectiveness. The aim of this modified Delphi study was to review the efficacy and safety of the different AK treatments, gain an understanding of the dermatologists' perspectives on their use, and provide guidelines for clinical practice.</p><p><strong>Materials and methods: </strong>This document corresponds to a modified Delphi consensus survey, based on a literature review and a single round of questionnaire.</p><p><strong>Results: </strong>The Delphi questionnaire was completed by 73 dermatologists from Germany, Italy, and Spain. Agreement was achieved for 78% of statements, while 11% showed discrepancies or were rejected.</p><p><strong>Conclusions: </strong>Key findings emphasize the importance of patient-centered approaches and treatment attributes beyond efficacy (e.g. tolerability or adherence). Understanding the mechanisms of action of treatments is vital for managing patients' and clinicians' expectations and optimizing outcomes. Alternative strategies for evaluating efficacy, including the Actinic Keratosis Area and Severity Index (AKASI) score and lesion reduction from baseline, were also highlighted.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2487657"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is colloidal oat an effective emollient ingredient for the prevention and treatment of atopic dermatitis in infants?","authors":"Joseph F Fowler, Lin Ma, James Bergman, Paul Horowitz, Tina Lavender, Lawrence F Eichenfield, Zoe Draelos, Simon G Danby, Michael J Cork","doi":"10.1080/09546634.2025.2487945","DOIUrl":"https://doi.org/10.1080/09546634.2025.2487945","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by barrier dysfunction and immune dysregulation, often leading to increased allergen penetration, sensitization, and secondary infections. Colloidal oat emollients are widely used in adult AD management, but their role in pediatric AD treatment, prevention, and allergy modulation remains under investigation.</p><p><strong>Methods: </strong>A comprehensive literature review evaluated clinical and preclinical studies on colloidal oat-containing emollients in pediatric AD treatment and prevention. Studies assessing skin barrier function, immune modulation, AD prevention, food allergy risk, and healthcare utilization were included.</p><p><strong>Results: </strong>Colloidal oat emollients improved skin hydration, reduced transepidermal water loss (TEWL), and supported barrier repair, leading to fewer AD flares and reduced reliance on steroid treatments. Studies suggest that early, consistent use of advanced emollient formulations may lower AD incidence in high-risk infants and reduce food sensitization rates. Real-world data indicate that patients using colloidal oat emollients have fewer clinic visits and lower overall healthcare costs. Concerns about oat sensitization remain unsubstantiated in most studies.</p><p><strong>Conclusion: </strong>Colloidal oat emollients are effective, well-tolerated, and cost-efficient for pediatric AD management. Their barrier-restorative and anti-inflammatory properties may reduce AD and allergy risk. Future research should focus on head-to-head emollient comparisons to optimize treatment strategies.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2487945"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy analysis of 5-aminolevulinic acid photodynamic therapy for vulvar lichen sclerosus in women of childbearing age.","authors":"Lijuan Yang, Qian Shang, Dongning Zhu, Yu Jia, Chunyu Shi, Yanling Dang","doi":"10.1080/09546634.2025.2497362","DOIUrl":"https://doi.org/10.1080/09546634.2025.2497362","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and long-term durability of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in treating vulvar lichen sclerosus (VLS) in women of childbearing age.</p><p><strong>Methods: </strong>Fifty-five patients with VLS who had failed long-term repeated pharmacological treatments (mean disease duration: 3.6 ± 1.4 years)were enrolled. All participants underwent four sessions of ALA-PDT. Follow-up evaluations were conducted for six months after treatment. Outcomes were assessed using the Cattaneo clinical symptom and sign score and the Dermatology Life Quality Index (DLQI) questionnaire at baseline, after four treatments, and at 3-6 months post-treatment.</p><p><strong>Results: </strong>At the 6-month follow-up, efficacy rates were 81.8% for pruritus relief, 67.3% for skin elasticity restoration, 63.6% for skin color improvement, and 72.7% for lesion area reduction. Pain was the only reported adverse reaction during treatment.</p><p><strong>Conclusion: </strong>20% ALA-PDT is a safe, effective, and durable therapeutic option for VLS with minimal side effects. Notably, it provides a viable alternative for patients unresponsive to conventional therapies.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2497362"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anatomical considerations for thread-based brow lifting and wrinkle treatment.","authors":"Gi-Woong Hong, Jovian Wan, Song-Eun Yoon, Sky Wong, Kyu-Ho Yi","doi":"10.1080/09546634.2024.2448265","DOIUrl":"10.1080/09546634.2024.2448265","url":null,"abstract":"<p><p>This review explores the anatomical considerations and technical aspects of thread lifting for the forehead and eyebrow, focusing on the relationships between vascular structures, muscular anatomy, and age-related changes in the forehead-eyebrow complex. It highlights the critical importance of understanding neurovascular pathways, particularly the supratrochlear and supraorbital vessels, as well as the appropriate thread placement techniques necessary for optimal outcomes. The review demonstrates that I-shaped threads, when placed beneath the frontalis muscle, provide a safer and equally effective alternative to traditional U-shaped designs. Additionally, the review emphasizes the significance of preoperative assessment, especially the evaluation of tissue mobility and adhesion patterns, in predicting procedural success. The review concludes that combining thread lifting with volumising monofilaments offers a comprehensive approach to rejuvenating the forehead-glabellar region, while minimizing the risk of complications. This study's clinical impact lies in its potential to enhance both the safety and efficacy of thread lifting procedures, offering practitioners a refined technique for esthetic rejuvenation of the forehead and eyebrow complex.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2448265"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective and safe surgery for keratinocyte skin cancer in the elderly over 80 years of age: a single-institution retrospective study of 345 patients over one year.","authors":"Luca D Fontana, Clara Richter, Ramon Lang, Christian Greis, Jürg Hafner","doi":"10.1080/09546634.2025.2461650","DOIUrl":"10.1080/09546634.2025.2461650","url":null,"abstract":"<p><strong>Objectives: </strong>As life expectancy rises and the population continues to age, physicians will be faced with an increasing number of elderly patients with keratinocyte cancer (KC). This study aims to better characterize KC surgery in patients over 80 years of age, with a particular focus on the incidence of postoperative complications.</p><p><strong>Methods: </strong>A retrospective study was conducted on all patients aged 80 years and older who underwent surgery for KC at the University Hospital of Zurich in 2022. Data were collected from operative and postoperative notes within six months after surgery.</p><p><strong>Results: </strong>A total of 565 tumors were removed from 345 patients, consisting mainly of basal cell carcinoma (46.5%) and squamous cell carcinoma (45.8%), including 24.2% clinically large tumors (>2 cm in diameter). A total of 26 complications were recorded, resulting in an overall complication rate of4.6%. Only one patient with a hematoma required surgical revision under local anaesthesia. Four cases of hemorrhage were solved by bed side ligations under local anaesthesia. Of the 26 recorded complications, 15 (58%) concerned wound dehiscence, requiring no further measures. The use of novel oral anticoagulants, lower extremity location, surgical specimen size >2 cm², and flap repair were found to be independent risk factors associated with a statistically higher incidence of complications.</p><p><strong>Conclusions: </strong>This study demonstrated that dermatologic surgery adapted to the geriatric population is relatively safe and effective, even for larger KC of several centimeters in diameter.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2461650"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab.","authors":"Francine Foss, Youn H Kim, Julia Scarisbrick, Oleg Akilov, Robert Ristuccia, Karen Dwyer, Wende Wu, Martine Bagot","doi":"10.1080/09546634.2024.2438794","DOIUrl":"10.1080/09546634.2024.2438794","url":null,"abstract":"<p><strong>Purpose: </strong>Mogamulizumab demonstrated improved outcomes <i>vs.</i> vorinostat across a range of disease and patient characteristics in patients with mycosis fungoides or Sézary syndrome in the MAVORIC trial.</p><p><strong>Materials and methods: </strong>This <i>post-hoc</i> analysis further examined MAVORIC data to assess factors associated with long-term response (ORR >12 months), time to next treatment (TTNT), and impact of concomitant steroid use, lymphopenia, and mogamulizumab-associated rash (MAR) on patient response.</p><p><strong>Results: </strong>A higher proportion of patients achieved ORR lasting ≥4, 6, 8, or 12 months in the mogamulizumab <i>vs.</i> vorinostat arm. Long-term response was also observed in mogamulizumab-treated patients with more advanced disease (stage IVA1 [17/20], B2 blood involvement [18/20], and SS [14/20]). PFS was significantly longer (9.4 <i>vs.</i> 3.1 months; <i>p</i> < 0.0001) in mogamulizumab <i>vs.</i> vorinostat-treated patients taking concomitant steroids. Mogamulizumab-treated patients experienced longer TTNT <i>vs.</i> vorinostat. Lymphopenia and MAR were associated with response to mogamulizumab.</p><p><strong>Conclusions: </strong>MAVORIC demonstrated greater efficacy with mogamulizumab <i>vs.</i> vorinostat in relapsed/refractory patients with CTCL, including those with more advanced disease. Concomitant steroid use improved ORR and PFS but did not impact vorinostat outcomes. Overall responses occurred more frequently in mogamulizumab-treated patients that developed lymphopenia than those that did not. A higher percentage of patients with MAR had an overall response than those without MAR.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2438794"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global onychomycosis management and the challenges of antifungal stewardship.","authors":"Aditya K Gupta, Elizabeth A Cooper, Eckart Haneke, Shari R Lipner, Ditte Marie L Saunte, Chander Grover, Avner Shemer, Bianca M Piraccini, Antonella Tosti, Roderick J Hay","doi":"10.1080/09546634.2025.2526073","DOIUrl":"https://doi.org/10.1080/09546634.2025.2526073","url":null,"abstract":"<p><strong>Purpose: </strong>Onychomycosis, in contrast to other routine superficial dermatophyte infections, is difficult to treat and poor outcomes are not unusual. Few guidelines for onychomycosis management have been published, and these vary considerably from region to region. To meet global antifungal stewardship (AFS) goals, there must be global management guidelines for clinicians to follow in their onychomycosis practice. We aimed to survey current practices for onychomycosis management across a variety of global regions and compare practices to published treatment guidelines, as well as to what degree the management practices may facilitate AFS practices.</p><p><strong>Materials and methods: </strong>An informal literature review was performed to identify regional onychomycosis guidelines. An online survey of our colleagues was distributed to assess current onychomycosis management practices and challenges for comparison with associated regional guidelines. Guidelines and practices were reviewed for adherence to the general AFS principles.</p><p><strong>Results: </strong>Our review of current practices shows that, despite guidelines, identification of the infecting species is often not obtained, and treatment provision does not strictly follow existing guidelines. Lack of laboratory access prevents diagnosis and antifungal susceptibility testing that can help provide targeted treatments and resistance surveillance. Better diagnostic methods are needed as a component to improve management decisions, and provide the reliable monitoring required for effective AFS. Broader clinical testing is needed to address knowledge gaps in onychomycosis therapy. Meeting these challenges must be a priority as antifungal resistance is quickly becoming a worldwide problem.</p><p><strong>Conclusions: </strong>As a reservoir for resistant strains, onychomycosis represents a significant future medical/economic burden. Future onychomycosis guidelines must address the challenge of resource limitations experienced by clinicians, as well as the challenge of balancing the need for AFS principles with the specific needs of onychomycosis therapy.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2526073"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144577430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy prediction model of hematoporphyrin monomethyl ether photodynamic therapy for facial port-wine stains.","authors":"Yuanbo Huang, Wen Ju, Lei Wang, Jun Yang, Mingye Bi","doi":"10.1080/09546634.2025.2531135","DOIUrl":"https://doi.org/10.1080/09546634.2025.2531135","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to identify factors influencing photodynamic therapy (PDT) efficacy in facial port-wine stains (PWS) and to develop a predictive model for treatment outcomes.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 863 patients with facial PWS who had undergone hematoporphyrin monomethyl ether photodynamic therapy (HMME-PDT). Multivariate logistic regression analysis was employed to identify factors influencing efficacy and to construct a nomogram prediction model.</p><p><strong>Results: </strong>A total of 265 patients (30.7%) obtained excellent results while 598 patients (69.3%) did not. The influencing factors identified included age, PWS location, type of PWS, prior treatment history, number of PDT sessions, and vascular and non-vascular features observed <i>via</i> dermoscopy. Receiver operating characteristic curve analysis revealed that the area under the curve for the training and validation cohorts was 0.80 and 0.81, respectively. The calibration curve closely approximated the ideal diagonal line, and the Hosmer-Lemeshow test indicated a good fit for the model in both the training (<i>p</i> = 0.73) and validation cohorts (<i>p</i> = 0.52). Clinical decision curve analysis demonstrated a significantly improved net benefit in both cohorts.</p><p><strong>Conclusions: </strong>Our findings provide dermatologists with an accurate and effective tool for predicting PDT efficacy, facilitating the individualized management of facial PWS.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2531135"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initiation of apremilast treatment decreases prescribed topical therapy amount in patients with psoriasis: a health insurance claims study in Japan.","authors":"Siddharth Chaudhari, Ryuichi Ogawa, Shinichi Imafuku, Hiroshi Saruwatari, Katarzyna Jabłońska, Kathy Tran","doi":"10.1080/09546634.2025.2535686","DOIUrl":"10.1080/09546634.2025.2535686","url":null,"abstract":"<p><strong>Objective: </strong>Effective systemic treatments for psoriasis may reduce the need for topical therapies. The objective of this study was to evaluate changes in topical prescriptions after apremilast initiation.</p><p><strong>Materials and methods: </strong>This retrospective cohort study was performed in the Japanese JMDC health insurance claims database. Adults with psoriasis initiating apremilast between 01/03/2018 and 31/07/2021 and prescribed topical therapies in the previous six months were eligible. Topical therapy prescription was compared between the six months preceding and the six months following apremilast initiation. Data from 319 patients were analyzed.</p><p><strong>Results: </strong>The cumulative amount (grams) of topical therapies prescribed decreased significantly following apremilast initiation from 195.8 ± 236.1 to 162.2 ± 230.9 for steroids (<i>p</i> < 0.001) and from 84.6 ± 89.6 to 77.1 ± 104.6 for vitamin D analogues (<i>p</i> = 0.018). No significant change was observed for fixed-dose combinations (from 133.2 ± 140.0 to 143.4 ± 136.8; <i>p</i> = 0.487) or total topical therapy (from 309.9 ± 272.3 to 301.0 ± 293.0; <i>p</i> = 0.131). For steroids, the reduction was only significant for 'very strong' potency steroids (-33.6 g; <i>p</i> = 0.001). Eighteen patients (6%) discontinued all topical therapy following apremilast initiation and 69 (22%) were prescribed fewer concomitant topical therapies.</p><p><strong>Conclusion: </strong>In conclusion, initiation of systemic apremilast treatment is associated with reduced prescription of topical therapies. Treatment with apremilast may decrease the burden of long-term exposure to topical therapies.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2535686"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144736464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of narrowband ultraviolet B phototherapy combination with tofacitinib in the treatment of vitiligo: a randomized controlled trial.","authors":"Xiaoyan Guo, Dongxu Zhang, Guangxiong Chen, Yijie Xie, Yibin Mao","doi":"10.1080/09546634.2025.2479567","DOIUrl":"https://doi.org/10.1080/09546634.2025.2479567","url":null,"abstract":"<p><strong>Background: </strong>This randomized control clinical trial aimed to evaluate the efficacy of tofacitinib combined with phototherapy narrowband ultraviolet B (UVB) in the treatment of vitiligo.</p><p><strong>Methods: </strong>A total of 136 vitiligo patients were randomized to UVB treatment (UVB group) or UVB treatment combined with tofacitinib (TOF-UVB group). The patients were followed up for 24 weeks. In post-treatment analysis of treatment outcomes, the vitiligo area severity index (VASI) and dermatology life quality index (DLQI) were measured. Serum levels of inflammatory factors including IL-17, IL-23, IFN-γ and IL-6, were measured with enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>In post-treatment analysis, significantly more patients in the TOF-UVB group (<i>n</i> = 63) showed effective recovery compared to the UVB group (<i>n</i> = 61). TOF-UVB group also demonstrated markedly lower VASI and DLQI scores than the UVB group. Pronouncedly lower levels of inflammatory factors were also observed.</p><p><strong>Conclusions: </strong>Our data suggest that UVB-TOF is potentially more effective than UVB alone in promoting recovery of vitiligo patients and reducing inflammatory factors.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2479567"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}